Home › Research › Topics › sedative-antipsychotic-harm-in-dementia
sedative-antipsychotic-harm-in-dementia
4 studies tagged sedative-antipsychotic-harm-in-dementia, dated 2015-03-01 to 2025-10-01. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Benzodiazepine or Antipsychotic Use and Mortality Risk Among Patients With Dementia in Hospice Care 2025-10-01
- Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study 2024-04-17
- Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm 2015-05-01
Studies
4 studies carry this tag.
Date range
2015 to 2025
Top journals
- BMJ 1
- JAMA Network Open 1
- JAMA internal medicine 1
- JAMA psychiatry 1
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
60/100
In this national case-control study of nursing home residents with ADRD receiving hospice care, initiation of benzodiazepine or antipsychotic use was associated with increased 180-day mortality.
-
Antipsychotic use compared with non-use in adults with dementia was associated with increased risks of stroke, venous thromboembolism, myocardial infarction, heart failure, fracture, pneumonia, and acute kidney injury, but not ventricular arrhythmia.
-
Compared with respective matched nonusers, individuals receiving haloperidol had an increased mortality risk of 3.8% (95% CI, 1.0%-6.6%; P Conclusions and relevance The absolute effect of antipsychotics on mortality in elderly patients with dementia may be higher than previously reported and increases with dose.
-
The most common anticholinergic classes used were tricyclic antidepressants, first-generation antihistamines, and bladder antimuscarinics.